2. Search Result
Search Result
Results for "

TLR9 activator

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

15

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-146244
    Agatolimod
    1 Publications Verification

    ODN 2006; PF-3512676; CpG 7909; ODN 7909

    		 Toll-like Receptor (TLR) Bacterial NO Synthase Apoptosis Infection Cancer
    Agatolimod ((ODN 2006; PF-3512676; CpG 7909)) is a TLR9 agonist and immunomodulator with an EC50 of 180 nM against human TLR9. Agatolimod activates and upregulates the expression of both TLR9 and TLR6, and mediates downstream signaling pathways via IRAK4, IRF5, IRF7. Agatolimod induces Th1-type innate and adaptive immune responses, activates various immune cells and promotes antigen presentation, regulates antibody levels and immune cell infiltration, upregulates the secretion of multiple cytokines, induces apoptosis and cell cycle arrest, enhances cytotoxicity, and clears intracellular Salmonella. Agatolimod is applicable to research on COVID-19, breast cancer, lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis .
    Agatolimod
  • HY-150751
    ODN TTAGGG
    3 Publications Verification

    ODN A151

    		 Toll-like Receptor (TLR) AIM2 Pyroptosis Interleukin Related Inflammation/Immunology
    ODN TTAGGG (ODN A151), an inhibitory oligonucleotide (ODN), is a TLR9, AIM2, and cGAS antagonist. ODN TTAGGG inhibits AIM2 inflammasome activation and cGAS activation through competition with DNA. ODN TTAGGG blocks AIM2-mediated Pyroptosis and inhibits IL-18 production. ODN TTAGGG has immunosuppressive effects and can be used in research on related autoimmune diseases such as lupus erythematosus . ODN TTAGGG sequence: 5'-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-3'.
    ODN TTAGGG
  • HY-150741
    ODN 2216
    1 Publications Verification

    		 Toll-like Receptor (TLR) IFNAR Interleukin Related Infection Inflammation/Immunology Cancer
    ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 interacts with TLR9 in the lysosomes of CD4 + T cells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4 + T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 + T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus .
    ODN 2216
  • HY-150741C
    ODN 2216 sodium
    1 Publications Verification

    		 Toll-like Receptor (TLR) Cancer
    ODN 2216 sodium is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 sodium interacts with TLR9 in the lysosomes of CD4 + T cells and activates feedback-dependent signaling pathways. ODN 2216 sodium induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 sodium not only induces the differentiation of CD4 + T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 + T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 sodium is widely used in studies related to breast cancer and systemic lupus erythematosus .
    ODN 2216 sodium
  • HY-150217
    CpG ODN 10101
    2 Publications Verification

    ODN 10101

    		 Toll-like Receptor (TLR) Infection Inflammation/Immunology
    CpG ODN 10101 (ODN 10101; CPG 10101) is a selective agonist targeting TLR9, a synthetic oligodeoxynucleotide modified with phosphate thioester. CpG ODN 10101 activates B cells and plasmacytoid dendritic cells (pDCs), inducing the production of cytokines and chemokines such as interferon-IFN-α, interferon-inducible protein IP-10, and 2'5'-oligoadenylate synthase (2'5'-OAS), regulating innate immunity and promoting Th1 adaptive immune responses. CpG ODN 10101 also possesses antiviral properties and enhances vaccine immunogenicity, making it suitable as an immunomodulator and vaccine adjuvant for vaccine development in chronic hepatitis C and infectious diseases such as melioidosis, pertussis, and respiratory syncytial virus (RSV) .
    CpG ODN 10101
  • HY-155864
    AJ2-30

    		NOD-like Receptor (NLR) mTOR Oligopeptide Cotransporter Inflammation/Immunology
    AJ2-30 is a SLCl5A4 inhibitor. AJ2-30 inhibits endolysosomal TLR7-9-mediated mTOR activation. AJ2-30 blocks endogenous NOD signaling. AJ2-30 can be used in inflammation studies .
    AJ2-30
  • HY-150751C
    ODN TTAGGG sodium
    3 Publications Verification

    ODN A151 sodium

    		 AIM2 Toll-like Receptor (TLR) Inflammation/Immunology
    ODN TTAGGG sodium, inhibitory oligonucleotide (ODN), is a TLR9, AIM2 and cGAS antagonist. ODN TTAGGG sodium is immunosuppressive and inhibits AIM2 inflammasome activation, as well as cGAS activation, by competing with DNA. ODN TTAGGG sodium can be used in the study of lupus erythematosus and other related autoimmune diseases. ODN TTAGGG sequence: 5'-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-3' .
    ODN TTAGGG sodium
  • HY-150750A
    ODN M362 sodium

    		Toll-like Receptor (TLR) Apoptosis Interleukin Related TNF Receptor IFNAR Inflammation/Immunology Cancer
    ODN M362 sodium is a TLR9 agonist that acts as a vaccine adjuvant. ODN M362 sodium activates mouse splenocytes, induces apoptosis in human hepatocellular carcinoma cells, upregulates proinflammatory cytokines in human hepatocellular carcinoma cells, and inhibits the proliferation of human hepatocellular carcinoma cells. ODN M362 sodium upregulates the expression of TLR9/TLR6, activates downstream signaling pathways via IRAK4 and IRF7, and strongly amplifies antigen-specific cellular immune responses to participate in innate immune activation. ODN M362 sodium can be used in research related to hepatocellular carcinoma and breast cancer .
    ODN M362 sodium
  • HY-148511
    Vidutolimod

    CMP-001

    		 Toll-like Receptor (TLR) IFNAR PD-1/PD-L1 Indoleamine 2,3-Dioxygenase (IDO) Cancer
    Vidutolimod (CMP-001) is a virus-like particle containing a TLR9 activator . Vidutolimod induces human peripheral blood mononuclear cells to secrete IFNα, and upregulates the gene expression of CXCL10, PDL1, IDO and CD80. Vidutolimod activates TLR9, which in turn triggers plasmacytoid dendritic cell activation, production of IFNγ and TNFα, induction of CXCL10, and recruitment of antitumor T cells. Vidutolimod causes influenza-like symptoms, hypotension and tumor regression, and its activity depends on the presence of anti-Qβ antibodies. Vidutolimod modulates monocyte function, promotes CD4 T cell proliferation, and activates multiple immune cell types in an environment with anti-Qβ antibodies. Vidutolimod prolongs the survival of tumor-bearing mice. Vidutolimod is used in research related to advanced melanoma, head and neck squamous cell carcinoma, and advanced non-small cell lung cancer .
    Vidutolimod
  • HY-101929
    CU-CPT17e
    3 Publications Verification

    		 Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    CU-CPT17e is a potent multi-Toll-like receptor (TLR) agonist that activates TLR3, TLR8, and TLR9.
    CU-CPT17e
  • HY-148511A
    Vidutolimod sodium

    CMP-001 sodium

    		 Toll-like Receptor (TLR) Cancer
    Vidutolimod sodium is a CpG-A oligodeoxynucleotide. Vidutolimod sodium is a Toll-like receptor 9 (TLR9) agonist, which activates plasmacytoid dendritic cells (pDCs) and triggers interferon alpha (IFNα) release, leading to a cascade of anti-tumor immune effects.
    Vidutolimod sodium
  • HY-150212
    Tilsotolimod

    IMO-2125

    		 Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    Tilsotolimod (IMO-2125) is a TLR9 agonist. Tilsotolimod activates the TLR9 signaling pathway, triggers downstream pro-inflammatory and immunostimulatory pathways, enhances the uptake and killing of cancer cells, and induces adaptive immune responses. Tilsotolimod is applicable to research related to melanoma and colorectal cancer .
    Tilsotolimod
  • HY-150212A
    Tilsotolimod sodium

    IMO-2125 sodium

    		 Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    Tilsotolimod (IMO-2125) sodium is a TLR9 agonist. Tilsotolimod sodium activates the TLR9 signaling pathway, triggers downstream pro-inflammatory and immunostimulatory pathways, enhances the uptake and killing of cancer cells, and induces adaptive immune responses. Tilsotolimod sodium is applicable to research related to melanoma and colorectal cancer .
    Tilsotolimod sodium
  • HY-177058
    DSP30

    		Toll-like Receptor (TLR) Mitosis Inflammation/Immunology
    DSP30 is a phosphorothioate cpG-oligodeoxynucleotide and a TLR9 agonist. DSP30 can activate immune system cells, including B cells and dendritic cells, by inducing proliferation and cytokine production.DSP30 can enhance the immunosuppressive function of bone marrow-multipotent mesenchymal stromal cells (BM-MSC). DSP30 combined with interleukin 2 (IL2) is an effective mitotic stimulant in B-cell disorders. DSP30 can be used for the genetic characteristic research and analysis of chronic lymphocytic leukemia (CLL) .
    DSP30
  • HY-150744A
    ODN 24888 sodium

    		Toll-like Receptor (TLR) Inflammation/Immunology
    ODN 24888 sodium is an guanine-modified inhibitory oligonucleotides (INH-ODN), shows potent inhibition on TLR7/TLR9-mediated signaling. ODN 24888 sodium impairs IFN-α level and NF-κB activation, inhibits IL-6 release. ODN 24888 sodium involves in immune and inflammatory responses, can be used as a vaccine adjuvant .
    ODN 24888 sodium
  • HY-162649
    TIC10g

    		Toll-like Receptor (TLR) NF-κB p38 MAPK Inflammation/Immunology
    TIC10g is a dual inhibitor for toll-like receptor 7 and 9 (TLR7 and TLR9), which inhibits TLR7 and TLR9 mediated TNF-α release in mouse macrophages (IC50 is 14.5 μM and 6.5 μM) and human B lymphocytes (IC50 is 7.69 μM and 11.5 μM). TIC10g inhibits the activation of NF-κB and MAPK, and exhibits anti-inflammatory activity against systemic lupus erythematosus and rheumatoid arthritis .
    TIC10g
  • HY-150744
    ODN 24888

    		Toll-like Receptor (TLR) Inflammation/Immunology
    ODN 24888 is an guanine-modified inhibitory oligonucleotides (INH-ODN), shows potent inhibition on TLR7/TLR9-mediated signaling. ODN 24888 impairs IFN-α level and NF-κB activation, inhibits IL-6 release. ODN 24888 involves in immune and inflammatory responses, can be used as a vaccine adjuvant .
    ODN 24888
  • HY-181884
    TLR9-IN-3

    		Inflammation/Immunology
    TLR9-IN-3 is a TLR9 antagonist with an IC50 of 0.4 μM. TLR9-IN-3 shows selectivity for TLR4 and TLR8, and inhibits CD69 activation in human whole blood with a corresponding IC50 of 1.1 μM. TLR9-IN-3 can be used in research related to pulmonary fibrosis .
    TLR9-IN-3
  • HY-174519
    Human TLR9 mRNA

    		mRNA Inflammation/Immunology
    Human TLR9 mRNA encodes the human toll like receptor 9 (TLR9) protein, a member of the Toll-like receptor (TLR) family which plays a fundamental role in pathogen recognition and activation of innate immunity. TLR9 mediates cellular response to unmethylated CpG dinucleotides in bacterial DNA to mount an innate immune response.
    Human TLR9 mRNA
  • HY-101929R
    CU-CPT17e (Standard)

    		Reference Standards Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    CU-CPT17e (Standard) is the analytical standard of CU-CPT17e (HY-101929). This product is intended for research and analytical applications. CU-CPT17e is a potent multi-Toll-like receptor (TLR) agonist that activates TLR3, TLR8, and TLR9.
    CU-CPT17e (Standard)
  • HY-177973
    Zoratolimod

    		Toll-like Receptor (TLR) Antibody-Oligonucleotide Conjugates (AOCs) Inflammation/Immunology Cancer
    Zoratolimod, one of the components of the AOC Mozistobart zoratolimod (HY-177568), is composed of an oligonucleotide that can activate TLR9 and linkers (HY-164181 Fmoc-protected DMT-Dt PEG2 NH2 amidite; HY-130907 Fmoc-N-PEG24-acid). Zoratolimod can be used to synthesize AOC drugs), for cancer immunology research .
    Zoratolimod

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: